Authors: Machover, D Delmas-Marsalet, B Misra, SC Gumus, Y Goldschmidt, E Schilf, A Frenoy, N Emile, JF Debuire, B Guettier, C Farrokhi, P Boulefdaoui, B Norol, F Parquet, N Ulusakarya, A Jasmin, C

Citation: D. Machover et al., Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma, ANN ONCOL, 12(10), 2001, pp. 1439-1443

Authors: Morariu-Zamfir, R Rocha, V Devergie, A Socie, G Ribaud, P Esperou, H Parquet, N Guardiola, P Dal Cortivo, L Bittencourt, H Garnier, F Traineau, R Marolleau, JP Chevret, S Gluckman, E

Citation: R. Morariu-zamfir et al., Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia, BONE MAR TR, 27(6), 2001, pp. 575-580

Authors: Milpied, N Vasseur, B Parquet, N Garnier, JL Antoine, C Quartier, P Carret, AS Bouscary, D Faye, A Bourbigot, B Reguerre, Y Stoppa, AM Bourquard, P de Ligny, BH Dubief, F Mathieu-Boue, A Leblond, V

Citation: N. Milpied et al., Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients, ANN ONCOL, 11, 2000, pp. 113-116

Authors: Parquet, N Reigneau, O Humbert, H Guignard, M Ribaud, P Socie, G Devergie, A Esperou, H Gluckman, E

Citation: N. Parquet et al., New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients, BONE MAR TR, 25(9), 2000, pp. 965-968

Authors: Ribaud, P Chastang, C Latge, JP Baffroy-Lafitte, L Parquet, N Devergie, A Esperou, H Selimi, F Rocha, V Derouin, F Socie, G Gluckman, E

Citation: P. Ribaud et al., Survival and prognostic factors of invasive aspergillosis after allogeneicbone marrow transplantation, CLIN INF D, 28(2), 1999, pp. 322-330